Pyoderma gangrenosum
Pyoderma gangrenosum هڪ نادر سوزش واري چمڙي جي بيماري آهي، جنهن ۾ دردناڪ پسٽول يا نوڊولس السر بڻجن ٿا ۽ وڌن ٿا. Pyoderma gangrenosum انفڪشنل بيماري نه آهي. علاج ۾ corticosteroids، ciclosporin، يا مختلف monoclonal antibodies شامل ٿي سگهن ٿا. اهو ڪنهن به عمر جي ماڻهن کي متاثر ڪري سگهي ٿو، پر عام طور تي 40 ۽ 50 سالن جي عمر وارن ماڻهن ۾ وڌيڪ ڏٺو ويندو آهي.
☆ AI Dermatology — Free Service
2022 ۾ جرمني مان Stiftung Warentest نتيجن، ModelDerm سان صارفين جي اطمينان صرف ادا ڪيل ٽيلي ميڊيسن مشوري جي ڀيٽ ۾ ٿورو گهٽ هئي.
2022 ۾ جرمني مان Stiftung Warentest نتيجن، ModelDerm سان صارفين جي اطمينان صرف ادا ڪيل ٽيلي ميڊيسن مشوري جي ڀيٽ ۾ ٿورو گهٽ هئي.
ulcerative colitis سان متاثر ٿيل شخص جي ٽنگ تي.
relevance score : -100.0%
ReferencesPyoderma gangrenosum چمڙي جي هڪ نادر حالت آهي، جيڪا ڳاڙهي يا واڱڻائي وارين ڪنارن سان دردناڪ السر پيدا ڪري ٿي. اهو سوزش واري بيماري جي طور تي درجه بندي ڪيو ويو آهي ۽ هڪ گروپ جو حصو آهي جنهن کي نيوٽروفيلڪ ڊرماتوز سڏيو ويندو آهي. Pyoderma gangrenosum جو سبب پيچيده آهي، جنهن ۾ جيني طور تي متاثر ٿيندڙ ماڻهن ۾ پيدائشي ۽ موافقت واري قوت مدافعت جا مسئلا شامل آهن. تازو، محققن بيماري جي شروعاتي نقطي طور بال جي ڦڦڙن تي ڌيان ڏنو آهي.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum هڪ نادر چمڙي جي حالت آهي جيڪا انتهائي دردناڪ السر پيدا ڪري ٿي. جيتوڻيڪ اسان ان جي سبب کي مڪمل طور تي نه سمجهون ٿا، پر ڄاڻون ٿا ته ان ۾ مدافعتي سيلن جي وڌندڙ سرگرمي شامل آهي. بيماري جو علاج اڃا تائين آسان ناهي. اسان وٽ مختلف دوائون موجود آهن جيڪي مدافعتي نظام کي دٻائن ٿيون يا ان جي سرگرمي کي تبديل ڪن ٿيون. ان سان گڏ، زخم جي علاج ۽ درد جي انتظام تي به ڌيان ڏنو ويندو آهي. Corticosteroids ۽ cyclosporine اڪثر علاج لاءِ پهريون انتخاب آهن، پر تازو بايولوجيڪل علاج جهڙوڪ TNF-α inhibitors جي استعمال تي وڌيڪ تحقيق ڪئي وئي آهي. اهي خاص طور تي انهن مريضن ۾ ترجيح ڏنل آهن جن کي ٻيون سوزش واريون حالتون به آهن، ۽ بيماري جي عمل کي روڪڻ ۾ مددگار ثابت ٿين ٿا.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
